(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
75% of Arab Israelis support Arab party joining government coalition post-war, survey reveals - 2Manual for Savvy Home Lighting Framework: Lights up Your Space
- 3Instructions to Expand Your Advantages from an Open Record Reward
- 4Find Unexpected, yet invaluable treasure Excursion Rentals
- 5The Best 10 Innovation Advancements of the Year
- Vote in favor of the juice that you love for its medical advantages!
- Most loved VR Game for Wellness: Which Keeps You Dynamic?
- Vote in favor of your Favored sort of footwear
- Figure out How to Keep up with Oral Wellbeing During Pregnancy
- The Difficulties of Getting a Green Card in the US
- 10 Hints for an Effective New employee screening
- Instructions to Grasp the Innovation Behind 5G Pinnacles\
- Commonsense Ways to work on Your Funds with a Restricted Pay
- Getting through a Lifelong Change: Individual Examples of overcoming adversity
